<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="54982"><DrugName>exeporfinium chloride (nasal gel formulation, Staphylococcus aureus infection), Destiny Pharma/China Medical System</DrugName><DrugNamesKey><Name id="42955167">exeporfinium chloride</Name></DrugNamesKey><DrugSynonyms><Name><Value>XF drugs, Destiny Pharma</Value></Name><Name><Value>XF series, Destiny Pharma</Value></Name><Name><Value>bacterial infection therapy (intranasal), Destiny Pharma</Value></Name><Name><Value>MRSA therapy (topical), Destiny Pharma</Value></Name><Name><Value>photodynamic therapy (bacterial infection), Destiny Pharma</Value></Name><Name><Value>bacterial infection therapy (PDT), Destiny Pharma</Value></Name><Name><Value>XF-73</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>CPT-1</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>XF-73 (nasal, MSSA/MRSA decolonisation), Destiny Pharma</Value></Name><Name><Value>exeporfinium chloride</Value><Types><Type>INN</Type></Types></Name><Name><Value>exeporfinium chloride  (nasal, MSSA/MRSA decolonisation), Destiny Pharma</Value></Name><Name><Value>exeporfinium chloride (nasal gel formulation, Staphylococcus aureus infection), Destiny Pharma/China Medical System</Value></Name><Name><Value>XF-73 (nasal, MSSA/MRSA decolonisation), Destiny Pharma/China Medical System</Value></Name><Name><Value>718638-68-7</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="27313">Destiny Pharma Ltd</CompanyOriginator><CompaniesPrimary><Company id="1037068">China Medical System Holdings Ltd</Company><Company id="27313">Destiny Pharma Ltd</Company></CompaniesPrimary><CrossReferences><SourceEntity id="54982" type="Drug"><TargetEntity id="417846" type="siDrug">Exeporfinium chloride</TargetEntity></SourceEntity><SourceEntity id="1037068" type="Company"><TargetEntity id="4295863681" type="organizationId">China Medical System Holdings Ltd</TargetEntity></SourceEntity><SourceEntity id="27313" type="Company"><TargetEntity id="4296912846" type="organizationId">Destiny Pharma PLC</TargetEntity></SourceEntity><SourceEntity id="308" type="ciIndication"><TargetEntity id="4176" type="siCondition"/></SourceEntity><SourceEntity id="40" type="ciIndication"><TargetEntity id="A49.9" type="ICD10"/><TargetEntity id="10060945" type="MEDDRA"/><TargetEntity id="D001424" type="MeSH"/><TargetEntity id="-1693440076" type="omicsDisease"/><TargetEntity id="800" type="siCondition"/></SourceEntity><SourceEntity id="790" type="ciIndication"><TargetEntity id="10056340" type="MEDDRA"/><TargetEntity id="D017719" type="MeSH"/><TargetEntity id="-1424289263" type="omicsDisease"/><TargetEntity id="495" type="siCondition"/></SourceEntity><SourceEntity id="1594" type="Action"><TargetEntity id="3994" type="Mechanism">Drugs Targeting Pseudomonas aeruginosa Proteins</TargetEntity><TargetEntity id="2409" type="Mechanism">Carbon Monoxide-Releasing Agents</TargetEntity><TargetEntity id="1060" type="Mechanism">Efflux Pump (Bacterial) Inhibitors</TargetEntity><TargetEntity id="4457" type="Mechanism">Drugs Targeting Staphylococcus aureus Proteins</TargetEntity><TargetEntity id="5306" type="Mechanism">Drugs Targeting Mycobacterium tuberculosis Proteins</TargetEntity><TargetEntity id="4563" type="Mechanism">Anti-Diphteria Toxin (Corynebacterium diphtheriae)</TargetEntity><TargetEntity id="3878" type="Mechanism">Drugs Targeting Bacterial Chaperones</TargetEntity><TargetEntity id="4493" type="Mechanism">Drugs Targeting Campylobacter jejuni Proteins</TargetEntity><TargetEntity id="3697" type="Mechanism">Drugs Targeting Escherichia coli Proteins</TargetEntity><TargetEntity id="5353" type="Mechanism">Drugs Targeting Clostridium tetani Proteins</TargetEntity><TargetEntity id="5053" type="Mechanism">Anti-Diphtheria Toxin</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C2">Phase 2 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="12">Qualified Infectious Disease Product</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="308">Staphylococcus aureus infection</Indication><Indication id="790">Diabetic foot ulcer</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="40">Bacterial infection</Indication></IndicationsSecondary><ActionsSecondary><Action id="1594">Antibacterial</Action><Action id="415">Radical donator</Action><Action id="799">Photosensitizer</Action><Action id="955">Antimicrobial permeability enhancer</Action></ActionsSecondary><Technologies><Technology id="619">Nasal formulation local</Technology><Technology id="66">Antibiotic</Technology><Technology id="774">Nasal gel formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>J1</Code><Name>SYSTEMIC ANTIBACTERIALS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-24T12:10:04.000Z</LastModificationDate><ChangeDateLast>2019-04-12T00:00:00.000Z</ChangeDateLast><AddedDate>2006-02-20T15:02:36.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="27313" linkType="Company"&gt;Destiny Pharma&lt;/ulink&gt; and its Chinese licensee &lt;ulink linkID="1037068" linkType="Company"&gt;China Medical Systems&lt;/ulink&gt; are developing   an intranasal gel formulation of exeporfinium chloride (XF-73), the lead in the company's XF series of porphyrin-based compounds  (CTP-1) that react with triplet oxygen to produce singlet oxygen when activated by light, for the potential treatment and prevention of post-surgical Staphylococcus aureus infection including methicillin resistant staphylococcus aureus (MRSA) and diabetic foot ulcer infections [&lt;ulink linkID="651145" linkType="Reference"&gt;651145&lt;/ulink&gt;], [&lt;ulink linkID="651298" linkType="Reference"&gt;651298&lt;/ulink&gt;], [&lt;ulink linkID="913331" linkType="Reference"&gt;913331&lt;/ulink&gt;], [&lt;ulink linkID="1329941" linkType="Reference"&gt;1329941&lt;/ulink&gt;], [&lt;ulink linkID="1960115" linkType="Reference"&gt;1960115&lt;/ulink&gt;], [&lt;ulink linkID="1987004" linkType="Reference"&gt;1987004&lt;/ulink&gt;], [&lt;ulink linkID="2139373" linkType="Reference"&gt;2139373&lt;/ulink&gt;]. By April 2019,  a new dermal infection clinical programme had been initiated with XF-73 targeting diabetic foot ulcer infections  [&lt;ulink linkID="2139373" linkType="Reference"&gt;2139373&lt;/ulink&gt;]. In October 2012, the drug was in phase II development    [&lt;ulink linkID="1329941" linkType="Reference"&gt;1329941&lt;/ulink&gt;]. In April 2017, the drug was still in phase II development in the US and EU. At that time, the company was planning a phase IIb trial in prevention of post-surgical infections from all strains of S aureus [&lt;ulink linkID="1922430" linkType="Reference"&gt;1922430&lt;/ulink&gt;]; in March 2019, the trial was to initiate in 2019 [&lt;ulink linkID="2134900" linkType="Reference"&gt;2134900&lt;/ulink&gt;]. In January 2019, Destiny Pharma expected to complete phase II trials of XF-73 in 2019 [&lt;ulink linkID="2113896" linkType="Reference"&gt;2113896&lt;/ulink&gt;]. In April 2018, a phase III trial was planned [&lt;ulink linkID="2021779" linkType="Reference"&gt;2021779&lt;/ulink&gt;]. By May 2008, Destiny Pharma was  seeking to outlicense the drug  with an appropriate global partner [&lt;ulink linkID="913331" linkType="Reference"&gt;913331&lt;/ulink&gt;]; in April 2017, the company was still seeking to outlicense its programs [&lt;ulink linkID="1922434" linkType="Reference"&gt;1922434&lt;/ulink&gt;]. In December 2017, China Medical Systems gained certain Asia rights to the product, excluding Japan [&lt;ulink linkID="1960115" linkType="Reference"&gt;1960115&lt;/ulink&gt;], [&lt;ulink linkID="1987004" linkType="Reference"&gt;1987004&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Destiny Pharma is also investigating a &lt;ulink linkID="106100" linkType="Drug"&gt;throat formulation of exeporfinium chloride&lt;/ulink&gt;, a  &lt;ulink linkID="60390" linkType="Drug"&gt;topical exeporfinium chloride&lt;/ulink&gt;  and other porphyrin-based compound &lt;ulink linkID="81392" linkType="Drug"&gt;XF-70&lt;/ulink&gt; for the potential treatment of bacterial skin infection.&lt;/para&gt;&lt;para&gt;The company was previously investigating the drug for the potential treatment of other antibiotic-resistant bacterial infections [&lt;ulink linkID="651145" linkType="Reference"&gt;651145&lt;/ulink&gt;]; however, no further development was reported  since June 2003.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In March 2018, XF-73 was granted Fast Track designation for the prevention of post-surgical Staphylococcal infections, such as MRSA [&lt;ulink linkID="2013994" linkType="Reference"&gt;2013994&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2015, the US FDA granted Qualified Infectious Disease Product  designation to  XF-73  for the prevention of post-surgical Staphylococcal infections [&lt;ulink linkID="1712195" linkType="Reference"&gt;1712195&lt;/ulink&gt;], [&lt;ulink linkID="1793332" linkType="Reference"&gt;1793332&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In April 2018, a phase III trial was expected by the end of 2019 [&lt;ulink linkID="2021779" linkType="Reference"&gt;2021779&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In January 2019, Destiny Pharma expected to complete phase II trials of XF-73 in 2019 [&lt;ulink linkID="2113896" linkType="Reference"&gt;2113896&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2018, 	the US FDA accepted an IND application, and  a phase II trial was to be initiated to evaluate the nasal anti-staphylococcal efficacy and clinical safety of XF-73 compared to placebo in pre-surgical patients at risk of infection. At that time, results from the trial were expected in 2019 [&lt;ulink linkID="2008026" linkType="Reference"&gt;2008026&lt;/ulink&gt;]. In April 2018, the IIb trial was to assess the efficacy of XF-73 against placebo in the nasal decolonization of S aureus in approximately 150 patients prior to surgical procedures. At that time, results from the trial were expected in 2H19 [&lt;ulink linkID="2021779" linkType="Reference"&gt;2021779&lt;/ulink&gt;]. In April 2019, phase IIb protocol was finalised and a 200 patient study  was expected to initiate later that month [&lt;ulink linkID="2139373" linkType="Reference"&gt;2139373&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  April 2017, the company was planning a phase IIb trial for the prevention of post-surgical infections from all strains of S aureus [&lt;ulink linkID="1922430" linkType="Reference"&gt;1922430&lt;/ulink&gt;]. In January 2019, this was still the case [&lt;ulink linkID="2113896" linkType="Reference"&gt;2113896&lt;/ulink&gt;]. In March 2019, the trial was expected to initiate in 2019 [&lt;ulink linkID="2134900" linkType="Reference"&gt;2134900&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2012, the drug was in phase II development [&lt;ulink linkID="1329941" linkType="Reference"&gt;1329941&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I/II&lt;/subtitle&gt;By October 2012, three phase I/II studies had been completed in Europe. Clinical safety, tolerability and efficacy data had been published from these trials [&lt;ulink linkID="1329941" linkType="Reference"&gt;1329941&lt;/ulink&gt;]. By April 2017, four phase I/IIa studies had been completed. Data showed excellent clinical safety profile,  well tolerated at multiple doses, anti-S aureus efficacy compared to placebo, and rapid action against S aureus [&lt;ulink linkID="1922434" linkType="Reference"&gt;1922434&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2012, a phase   I/IIa, placebo-controlled trial began in patients (n = &amp;gt;50) in the US after an IND was opened. The trial would be funded by the &lt;ulink linkID="20520" linkType="Company"&gt;NIAID&lt;/ulink&gt; [&lt;ulink linkID="1274705" linkType="Reference"&gt;1274705&lt;/ulink&gt;], [&lt;ulink linkID="1329941" linkType="Reference"&gt;1329941&lt;/ulink&gt;],   [&lt;ulink linkID="1463797" linkType="Reference"&gt;1463797&lt;/ulink&gt;]; in October 2012, the phase I/IIa trial (&lt;ulink linkID="87205" linkType="Protocol"&gt;NCT01592214&lt;/ulink&gt;; 11-0007)  was expected to complete in May 2013 [&lt;ulink linkID="1329971" linkType="Reference"&gt;1329971&lt;/ulink&gt;]. In May 2013, part II of the trial was initiated which was to evaluate efficacy of the drug. Part I of the trial investigated safety, tolerability and distribution of the drug [&lt;ulink linkID="1424622" linkType="Reference"&gt;1424622&lt;/ulink&gt;]. In September 2016, results from the trial were reported. In the trial, part 1 evaluated safety in eight volunteers and part 2 evaluated 0.5 and 2.0 mg/g of exeporfinium chloride and two viscosities (2 and 4%) applied into the nostrils for five days. Data demonstrated that both the concentrations were safe and well-tolerated. Also, exeporfinium chloride rapid anti-staphylococcal effect after day 1, with 2.0 mg/g gel that showed a statistical difference against placebo, which was sustained throughout dosing [&lt;ulink linkID="1793332" linkType="Reference"&gt;1793332&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In January 2019, positive phase I data conducted in the US were reported. The study enrolled 35 volunteers who received two XF-73 nasal gel clinical formulations at anti-Staphylococcal concentrations (0.05% and 0.2% w/w) daily for 21 consecutive days on intact and abraded skin. Data demonstrated that both XF-73 concentrations yielded mean cumulative irritations scores which were significantly lower than the mean cumulative irritancy score of distilled water (p &amp;lt; 0.0001). The trial did not report any XF-73 adverse events during the study and no XF-73 was detected in blood samples taken, confirming earlier dermal and nasal clinical trials which also demonstrated no XF-73 appeared in the bloodstream, and reinforcing its excellent safety profile [&lt;ulink linkID="2114206" linkType="Reference"&gt;2114206&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2018, a phase I dermal safety study was initiated in 30 subjects in the US, to assess the potential skin irritation of XF-73. The trial had to be completed in order to initiate a phase IIb trial and, an additional phase I dermal safety study was to be completed in 200 subjects before the initiation of a phase III study. At that time, the additional trial was expected to be completed in 2019 [&lt;ulink linkID="2021779" linkType="Reference"&gt;2021779&lt;/ulink&gt;]. In July 2018, positive data from a blinded, placebo-controlled trial with pharmacokinetic sampling were reported. Data demonstrated that XF-73 in aqueous solution, at high concentrations, when applied daily for five days to intact and abraded skin (by tape stripping) had a similar irritancy potential to water under occluded (covered) conditions in a shorter version of an industry standard cumulative irritancy dermal safety study. Further, the data also supports the profile of XF-73 as new treatment options for dermal infections. At that time, a second phase I trial with XF-73 nasal gel formulation would be completed later in 2018 in a similar skin irritation potential safety volunteer trial [&lt;ulink linkID="2057272" linkType="Reference"&gt;2057272&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2012, combined data from two phase I trials were presented at the 22nd ECCMID in London, UK. Healthy volunteers (n = 77)  confirmed to be nasal carriers of Staphylococcus aureus were administered exeporfinium chloride (0.125 to 2.0 mg/g in six cohorts) or placebo applied to the anterior nares 2 to 3 times a day for 5 days. The agent was well tolerated, and was shown to be locally active, with significant reductions in S aureus counts within 1 to 2 days of treatment initiation [&lt;ulink linkID="1274893" linkType="Reference"&gt;1274893&lt;/ulink&gt;], [&lt;ulink linkID="1277230" linkType="Reference"&gt;1277230&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 2007, Destiny received approval from the MHRA to conduct phase I trials. By April 2008, the phase I trials had been completed and further clinical studies were planned for 2008 [&lt;ulink linkID="913331" linkType="Reference"&gt;913331&lt;/ulink&gt;]. In September 2010, data from a randomized, placebo-controlled, phase I study in S aureus subjects were presented at the 50th ICAAC meeting in Boston, MA. A total of 45 otherwise healthy persistent nasal carriers of S aureus were treated bid with increasing doses of exeporfinium chloride or placebo, over a 5-day period. Treatment was well tolerated with no serious adverse events reported. All subjects receiving 0.5 mg/g experienced a reduction in S aureus colonization after the first dose; at 5-days post-dose, 100% of individuals reported an absence of S aureus or a scant level of disease. At 14-days post-dose, a total of 4 volunteers were still free from colonization [&lt;ulink linkID="1126253" linkType="Reference"&gt;1126253&lt;/ulink&gt;], [&lt;ulink linkID="1130288" linkType="Reference"&gt;1130288&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Diabetic foot ulcer&lt;/subtitle&gt;By April 2019,  a new dermal infection clinical programme had been initiated with XF-73 targeting diabetic foot ulcer infections  [&lt;ulink linkID="2139373" linkType="Reference"&gt;2139373&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By April 2017, data shown XF-73's ability to kill bacteria within biofilms; the minimum biofilm eradication concentration of the drug unchaged compared to standard MIC, in S aureaus models [&lt;ulink linkID="1922434" linkType="Reference"&gt;1922434&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2009, preclinical data were presented at SMi's 11th Annual Superbugs and Superdrugs Conference in London, UK. Using standard time-kill methodologies at 4-times the MIC in exponential-phase cultures of S aureus (SH1000) in growth media, exeporfinium chloride killed bacteria within 15 min; this was comparable with daptomycin and tetracycline which had no marked effect on S aureus concentration within 25 min. In a study performed in the predominant US community-associated MRSA strain NRS 384 (USA-300), no MRSA resistance developed to exeporfinium chloride after 55 passages. The MRSA strain developed resistance to the &lt;ulink linkID="3665" linkType="Drug"&gt;mupirocin&lt;/ulink&gt;, &lt;ulink linkID="51430" linkType="Drug"&gt;fusidic acid&lt;/ulink&gt; and daptomycin within five passages. At passage 55, the MIC values for mupirocin, fusidic acid, daptomycin and exeporfinium chloride were 256, 512, 32 and 0.5 mg/l, respectively. Using the Calgary Biofilm Device, exeporfinium chloride and XF-70 were determined to have a minimum biofilm eradication concentration (MBEC) of 2 microg/ml for SH1000 which was comparable with values of greater than 256 microg/ml for daptomycin, &lt;ulink linkID="44401" linkType="Drug"&gt;vancomycin&lt;/ulink&gt;, &lt;ulink linkID="44438" linkType="Drug"&gt;ciprofloxacin&lt;/ulink&gt;, fusidic acid and tetracycline in the same strain. Furthermore, in cold cultured SH1000 at 4-times the MIC, exeporfinium chloride and XF-70 demonstrated cidal activities, unlike daptomycin, vancomycin and &lt;ulink linkID="3164" linkType="Drug"&gt;fosfomycin trometamol&lt;/ulink&gt; [&lt;ulink linkID="993529" linkType="Reference"&gt;993529&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2008, preclinical data on exeporfinium chloride were presented at the 18th ECCMID meeting in Barcelona, Spain. Activity of exeporfinium chloride against a diverse group of Gram-positive clinical and control organisms showed MIC values  against all isolates tested of 0.25 to 4 mg/l. HA-MRSA and CA-MRSA MIC values ranged between 0.5 to 1 mg/l. Enterococci, including 5 isolates that were vancomycin resistant, had a similar susceptibility range of 0.5 to 2 mg/l. Exeporfinium chloride also showed activity towards the anaerobes tested, with MIC values between 0.25 to 4 mg/l. These results included two clinical isolates of Clostridium difficile demonstrating MIC values of 1 mg/l, one of which was a toxin-producing strain. The majority of MBC values were equal to the MIC values with only a few isolates showing MBC values within 1 to 2 dilutions. Additionally, mutational resistance to exeporfinium chloride did not occur in vitro compared with fusidic acid, after 55 passages [&lt;ulink linkID="900691" linkType="Reference"&gt;900691&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2005, Destiny reported that   XF drugs were effective against all tested strains of S aureus, including MRSA. The compounds were highly bactericidal with MIC values of around 0.06 g/ml against MRSA. In vivo, XF drugs eradicated 99.99% of MRSA with no safety issues [&lt;ulink linkID="651145" linkType="Reference"&gt;651145&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2004, in vitro study results were reported showing that the number of bacteria was reduced by 3 to 5.8 log10 CFU/ml after 5 min incubation with XF drugs and a light source. However,  incubation times of 1 to 4 h did not improve phototoxicity. In contrast, the uptake of the XF drugs by keratinocytes and fibroblasts was more time-dependent [&lt;ulink linkID="651298" linkType="Reference"&gt;651298&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;XF-70 and exeporfinium chloride are both cationic diporphyrin-based compounds. CTP-1 is a cationic triporphyrin compound [&lt;ulink linkID="651298" linkType="Reference"&gt;651298&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2005, Destiny secured a STG 3 million investment to support development of XF drugs up to phase II trials [&lt;ulink linkID="651145" linkType="Reference"&gt;651145&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2005, the company filed &lt;ulink linkID="PA3073218" linkType="Patent"&gt;WO-2006000765&lt;/ulink&gt; claiming porphyrin-derived compounds activated with photodynamic or sonodynamic therapy for the treatment of resistant bacterial infections. A similar patent, &lt;ulink linkID="PA2902662" linkType="Patent"&gt;WO-2004056828&lt;/ulink&gt; was submitted in December 2003.&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="27313">Destiny Pharma Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate>2012-03-26T00:00:00.000Z</StatusDate><Source id="1274705" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27313">Destiny Pharma Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate>2012-10-10T00:00:00.000Z</StatusDate><Source id="1329971" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27313">Destiny Pharma Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>2019-04-09T00:00:00.000Z</StatusDate><Source id="2139373" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1037068">China Medical System Holdings Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate>2017-12-01T00:00:00.000Z</StatusDate><Source id="1987004" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="27313">Destiny Pharma Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate>2008-04-30T00:00:00.000Z</StatusDate><Source id="913331" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27313">Destiny Pharma Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2001-12-31T00:00:00.000Z</StatusDate><Source id="651145" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="27313">Destiny Pharma Ltd</OwnerCompany><Country id="US">US</Country><Indication id="308">Staphylococcus aureus infection</Indication><AwardedIndication>Prevention of post-surgical staphylococcal infections</AwardedIndication><DesignationType id="2">Prevention</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-03-15T00:00:00.000Z</MileStoneDate><Source id="2013994" type="PR"/></Row><Row><RegulatoryDesignation id="12">Qualified Infectious Disease Product</RegulatoryDesignation><OwnerCompany id="27313">Destiny Pharma Ltd</OwnerCompany><Country id="US">US</Country><Indication id="308">Staphylococcus aureus infection</Indication><AwardedIndication>Prevention of post-surgical staphylococcal infections</AwardedIndication><DesignationType id="2">Prevention</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2015-11-11T00:00:00.000Z</MileStoneDate><Source id="1712195" type="PR"/></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1037068">China Medical System Holdings Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="21241">The University of Aston In Birmingham</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="27313">Destiny Pharma Ltd</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="2">Drug - Screening/Evaluation</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C[N+](C)(C)CCCOc1ccc(cc1)c2/c3ccc([nH]3)/cc/4\nc(/c(c\5/cc/c(/[nH]5)c/c6n\c2\C=C6)/c7ccc(cc7)OCCC[N+](C)(C)C)C=C4.[Cl-].[Cl-]</Smiles><Smiles>CCCCCCCCCCCOc1ccc(cc1)c2/c3ccc([nH]3)/c(c/4\nc(/c(c\5/cc/c(/[nH]5)c(/c6n\c2\C=C6)\c7ccc(cc7)OCCC[N+](C)(C)C)/c8ccc(cc8)OCCC[N+](C)(C)C)C=C4)/c9ccc(cc9)OCCC[N+](C)(C)C</Smiles></StructureSmiles><Deals><Deal id="136003" title="NIAID to evaluate Destiny Pharma's XF-73 for staphylococcus infection"/><Deal id="242522" title="CMS to develop Destiny Pharma's anti-infective portfolio including XF-73, XF-70 and DPD-207, in China and other Asian countries ex-Japan   "/><Deal id="248391" title="Aston University to examine and assess compounds from the Destiny Pharma's XF-platform against serious drug resistant infections"/></Deals><PatentFamilies><PatentFamily id="1658999" number="WO-2004056828" title="Novel compounds and uses thereof"/><PatentFamily id="888735" number="WO-2010046663" title="Novel uses"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Solvias AG" id="1003662"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Destiny Pharma Ltd" id="27313"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>